Cell No. : Cell Name
RCB1897 : K562
update : 2022/12/20
|
| Comment | Human cell line derived from chronic myelogenous leukemia. Differentiate into mature erythrocytes. TKG0210 (Deposited from Tohoku Univ.). |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Obinata, Masuo
|
| Originator |
Lozzio, C.B. & Lozzio, B.B.
|
| Year of deposit |
2004
|
| Original cell |
TKG0210
|
| Animal |
human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Gender |
Female
|
| Age at sampling |
53 years
|
| Tissue |
pleural effusion
|
| Disease name |
chronic myelogenous leukemia
|
| Classification |
cancer
|
| History |
Cell Resource Center for Biomedical Research, Tohoku University（TKG0210）
|
|
Lifespan |
infinite
|
| Morphology |
lymphoblast-like
|
| Cellosaurus(Expasy) |
CVCL_0004
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Suspension cells
|
| Medium and additives |
|
RPMI1640 + 10% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
dilution
|
Culture information
|
Passage ratio |
|
1 : 8 split
|
| SC frequency |
|
Subculture : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma |
|
(-)
|
| Virus (HIV) |
|
LT 400
|
| Isozyme |
|
LD, NP
|
| Reference information |
Reference |
5
|
| User's Publication |
10
|
| Reference |
|
5042
Haruta Y, Seon BK.
Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6.
Proc Natl Acad Sci U S A
1986
83(20):7898-902
PubMed ID: 3464004
DOI: 10.1073/pnas.83.20.7898
|
|
4603
Lozzio BB, Lozzio CB.
Properties and usefulness of the original K-562 human myelogenous leukemia cell line.
Leuk Res
1979
3(6):363-70
PubMed ID: 95026
DOI: 10.1016/0145-2126(79)90033-x
|
|
969
Rutherford TR, Clegg JB, Weatherall DJ.
K562 human leukaemic cells synthesise embryonic haemoglobin in response to haemin.
Nature
1979
280(5718):164-5
PubMed ID: 95354
DOI: 10.1038/280164a0
|
|
970
Andersson LC, Jokinen M, Gahmberg CG.
Induction of erythroid differentiation in the human leukaemia cell line K562.
Nature
1979
278(5702):364-5
PubMed ID: 570644
DOI: 10.1038/278364a0
|
|
4602
Lozzio CB, Lozzio BB.
Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome.
Blood
1975
45(3):321-34
PubMed ID: 163658
|
| User's Publication |
|
20321
Izumi K, Shindo T, Ngo HT, Nakayama-Hosoya K, Akahane K, Tamai M, Nguyen TTT, Kawana-Tachikawa A, Inukai T, Takaori-Kondo A.
KIR3DL1 Allotype-Dependent Modulation of NK Cell Immunity against Chronic Myeloid Leukemia.
Immunohorizons
2021
5(8):687-702
PubMed ID: 34433624
DOI: 10.4049/immunohorizons.2100054
|
|
11912
Chen Z, Nishimura N, Okamoto T, Wada K, Naora K.
Molecular Mechanism of Matrine from Sophora alopecuroides in the Reversing Effect of Multi-Anticancer Drug Resistance in K562/ADR Cells.
Biomed Res Int
2019
PubMed ID: 31871929
DOI: 10.1155/2019/1269532
|
|
12489
Anuchapreeda S, Rungrojsakul M, Tima S, Chiampanichayakul S, Krig SR.
Co-activation of WT1 and AP-1 proteins on WT1 gene promoter to induce WT1 gene expression in K562 cells
Cell Signal
2019
53:339-347
PubMed ID: 30395942
DOI: 10.1016/j.cellsig.2018.11.001
|
|
4269
Hirao T, Yamaguchi M, Kikuya M, Chibana H, Ito K, Aoki S.
Altered intracellular signaling by imatinib increases the anti-cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells.
Cancer Sci.
2018
PubMed ID: 29121435
DOI: 10.1111/cas.13442
|
|
14533
Zhi Chen, Nobuhiro Nishimura, Takayuki Okamoto, Koichiro Wada, Kohji Naora
ABCB1-mediated multi-drug resistance in leukemic K562/ADR cells was reversed by Matrine, the main ingredient from Sophora alopecuroides
Proceedings for Annual Meeting of The Japanese Pharmacological Society
2018
WCP2018:PO3-7-14
DOI: 10.1254/jpssuppl.wcp2018.0_po3-7-14
|
|
13998
Nakai W, Yoshida T, Diez D, Miyatake Y, Nishibu T, Imawaka N, Naruse K, Sadamura Y, Hanayama R.
A novel affinity-based method for the isolation of highly purified extracellular vesicles
Sci Rep
2016
6:33935
PubMed ID: 27659060
DOI: 10.1038/srep33935
|
|
14001
Bologna-Molina R, Takeda Y, Kuga T, Chosa N, Kitagawa M, Takata T, Ishisaki A, Mikami T.
Expression of Wilms' tumor 1 (WT1) in ameloblastomas
J Oral Sci
2016
58(3):407-13
PubMed ID: 27665981
DOI: 10.2334/josnusd.15-0546
|
|
7421
Zhang B, Shimada Y, Kuroyanagi J, Ariyoshi M, Nomoto T, Shintou T, Umemoto N, Nishimura Y, Miyazaki T, Tanaka T.
In vivo selective imaging and inhibition of leukemia stem-like cells using the fluorescent carbocyanine derivative, DiOC5(3)
Biomaterials
2015
52:14-25
PubMed ID: 25818410
DOI: 10.1016/j.biomaterials.2015.02.009
|
|
13885
Umsumarng S, Pitchakarn P, Sastraruji K, Yodkeeree S, Ung AT, Pyne SG, Limtrakul P.
Reversal of human multi-drug resistance leukaemic cells by stemofoline derivatives via inhibition of P-glycoprotein function
Basic Clin Pharmacol Toxicol
2015
116(5):390-7
PubMed ID: 25265513
DOI: 10.1111/bcpt.12331
|
|
13882
Yamagishi N, Nakao R, Kondo R, Nishitsuji M, Saito Y, Kuga T, Hatayama T, Nakayama Y.
ncreased expression of sorcin is associated with multidrug resistance in leukemia cells via up-regulation of MDR1 expression through cAMP response element-binding protein
Biochem Biophys Res Commun
2014
448(4):430-6
PubMed ID: 24796664
DOI: 10.1016/j.bbrc.2014.04.125
|
Back
Top
CELL BANK Website